ISPOR 8th EUROPEAN CONGRESS - Florencja 2005

Lista polskich prac przedstawionych w ramach 8 Europejskiego Kongresu ISPOR:

THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES
Jakubczyk MK1, Niewada M2, Kowalik E3

1Warsaw School of Economics, Warsaw, Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3 Institute of Cardiology, Warsaw, Poland

THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER IN POLISH SETTINGS

Macioch T1, Niewada M2, Golicki D1, Kamiński B3, Jakubczyk M4
1Medical University of Warsaw, Warsaw, Woj. Mazowieckie, Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3 Warsaw School of Economics, Warszawa, mazowieckie, Poland; 4 Warsaw School of Economics, Warsaw, Poland

LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND

Pietrasik AL1, Niewada M2, Budaj A3, Kochman J1, Horszczaruk G1, Gabriel S4, Spiesser J5, Yuan Y6
1Medical University of Warsaw, Warsaw, Warsaw, Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3 Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland; 4 sanofi-aventis, Bagneux, France; 5 Sanofi-Synthelabo Recherche, Bagneux, France; 6 Bristol-Myers Squibb Company, Plainsboro, NJ, USA

THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS

Kamiński B1, Niewada M2, Latek M1, Lis J3, Gierczynski J3
1Warsaw School of Economics, Warszawa, mazowieckie, Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3 Sanofi-aventis Poland, Warsaw, Poland

SHOULD WE LOOK FOR A NEW APPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?

Sieradzki J1, Kinalska I2, Niewada M3, Faluta T4, Czech M4, Latek M5, Wilkins A4, Szczepanski M4, Pachocki R4 1Medical College, Jagiellonian University in Krakow, Krakow, Poland; 2 Medical University in Bialystok, Bialystok, Poland; 3 Medical University of Warsaw, Warsaw, Poland; 4 Servier Poland, Warsaw, Poland; 5 Warsaw School of Economics, Warszawa, Mazowieckie, Poland

COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND

Golicki D1, Latek M2, Niewada M1, Glogowski C3, Kukwa W1, Macioch T1
1Medical University of Warsaw, Warsaw, Poland; 2 Warsaw School of Economics, Warsaw, Poland; 3 GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland

ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME

Ruciński P1, Kutarski A1, Latek M2, Kamiński B2, Szczasny M1, Widomska-Czekajska T1, Wdowiak L1
1 Medical University of Lublin, Lublin, Lubelskie, Poland; 2 Warsaw School of Economics, Warszawa, Mazowieckie, Poland

EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN POLAND

Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2 Servier Poland, Warsaw, Poland

COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND

Pirozynski M1, Bartminski W2, Czech M2, Faluta T2, Pachocki R2
1Medical Center for Postgraduate Education, Warsaw, Poland; 2 Servier Poland, Warsaw, Poland

COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND.

Kawalec P1, Lis J2, Gierczynski J2
1Jagiellonian University, Krakow, Poland; 2 Sanofi-aventis Poland, Warsaw, Poland

COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

Skowron A, Brandys J
Jagiellonian University, Cracow, Malopolska, Poland

THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS: A POLISH ANALYSIS

Orlewska E1, Lis J2, Gierczynski J3
1Centre for Pharmacoeconomics, Warsaw, Poland; 2 Sanofi-aventis Poland, Warsaw, Poland; 3 sanofi-aventis group, Warsaw, Poland

COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND

Glinka M, Kowalik E, Wlodarska EK, Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland

COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND

Kowalik E, Glinka M, Wlodarska EK, Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland

COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI PATIENTS IN POLAND

Dewilde S1, Opolski G2, Brown R3
1The MEDTAP Institute at UBC, Brussels, Belgium; 2 Medical Academy, Warsaw, Poland; 3 MedTap Institute at UBC, London, United Kingdom

TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENT THROMBOPROPHYLAXIS IN POLAND

Orlewska E1, Lis J2
1Centre for Pharmacoeconomics, Warsaw, Poland; 2 Sanofi-aventis Poland, Warsaw, Poland

APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS) TO MONITOR QUALITY AND TO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER - AN EXAMPLE OF MEETING ISO 9001:2000 REQUIREMENTS BY THE CARDIOSURGICAL UNIT IN POLAND.

Koltowski LN1, Kosela J2
1Leon Kozminski Academy of Enterpreneurship and Management, Warsaw, Poland; 2 University of Greenwich, London, United Kingdom